Status:

COMPLETED

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Lead Sponsor:

Actelion

Conditions:

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

Eligibility Criteria

Inclusion

  • Key inclusion criteria:
  • Signed informed consent prior to any study-mandated procedure.
  • Male and female subjects aged 18 years and above with a history of recurrent multiple weekly RP attacks secondary to SSc.
  • Women of childbearing potential must agree to use a reliable method of birth control.
  • Key exclusion criteria:
  • Known moderate or severe hepatic impairment (i.e. Child-Pugh C).
  • Known hypersensitivity to selexipag or drugs of the same class, or any of their excipients.
  • Subjects who have received prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostenol, iloprost, beraprost) within 3 months prior to the screening visit.
  • Subjects who have received a Phosphodiesterase type 5 (PDE-5) inhibitor within 1 week prior to the screening visit.
  • Any dose change or initiation of any of the following drugs within 1 month prior to the screening visit: Calcium channel blockers, Nitrates or nitric oxide donors, ERA's, Alpha-blockers, Antithrombotic agents, NSAIDs (occasional use allowed), Angiotensin Converting Enzyme (ACE) inhibitors, Beta-blockers, Clonidine, Systemic corticosteroids, Fluoxetine.
  • Severe renal insufficiency (at randomization).
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

Exclusion

    Key Trial Info

    Start Date :

    October 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2015

    Estimated Enrollment :

    74 Patients enrolled

    Trial Details

    Trial ID

    NCT02260557

    Start Date

    October 1 2014

    End Date

    June 1 2015

    Last Update

    February 3 2025

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis | DecenTrialz